Crinetics Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
forms, and several top payers adding the drug to formularies (many with label-aligned prior authorization and no step edits), while the company uses a Quick Start program for about half of new patients as access builds. Atumelnant , described as the first ACTH receptor antagonist tested in humans, produced rapid and large reductions in 24-hour urinary free cortisol in an NIH study and will enter a global "seamless" phase II/III EQUILIBRIUM ADCS trial in H1 to define dose and glucocorticoid replacement strategy. Crinetics reported Q4 revenue of $6.2M (including $5.4M from PALSONIFY), used $326.2M cash in 2025, and after a Jan 2026 offering has roughly $1.4B in cash and investments, which management says supports operations into 2030; 2026 GAAP operating expense guidance is $600–650M (non-GAAP $480–520M). Interested in Crinetics Pharmaceuticals, Inc.? Here are five stocks we like better. Crinetics Pharmaceuticals (NASDAQ:CRNX) executives highlighted early commercial momentum for
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals (CRNX) had its price target lowered by Citizens Jmp from $105.00 to $96.00. They now have a "market outperform" rating on the stock.MarketBeat
- Crinetics (CRNX) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
CRNX
Earnings
- 2/26/26 - Beat
CRNX
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/3/26 - Form 144
- CRNX's page on the SEC website